

Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat

Markus Magerl,^{1,2} Inmaculada Martinez-Saguer,³ William R. Lumry,⁴ John Anderson,⁵ Jonathan A. Bernstein,⁶ Mauro Cancian,⁷ Danny M. Cohn,⁸ Henriette Farkas,⁹ H. Henry Li,¹⁰ James Hao,¹¹ Michael D. Smith,¹¹ Paolo Bajcic,¹¹ Paul K. Audhya,¹¹ Petra Staubach-Renz,¹² Emel Aygören-Pürsün¹³

¹Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; ³HZRM Hämostase Center Rhein Main, Frankfurt, Germany; ⁴AARA Research Center, Dallas, TX, USA; ⁵Clinical Research Center of Alabama, an affiliate of AllerVie Health, Birmingham, AL, USA; ⁶University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, OH, USA; ⁷Departmental Allergy Division, Department of Systems Medicine, University of Padua, Padua, Italy; ⁸Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands; ⁹Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; ¹⁰Institute for Asthma and Allergy, Wheaton, MD, USA; ¹¹KalVista Pharmaceuticals, Salisbury, UK, and Framingham, MA, USA; ¹²Department of Dermatology, University Medical Center, Mainz, Germany; ¹³University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany

Disclosures: Markus Magerl has received grants, honoraria, and/or medical writing support from KalVista Pharmaceuticals, CSL Behring, Takeda, Pharming, BioCryst, Novartis, Octapharma, Intellia Therapeutics, and Pharvaris.

Background

- Treatment guidelines recommend people living with HAE treat attacks with on-demand medication as early as possible to arrest progression of swelling, thereby reducing severity and morbidity, shortening total attack duration, and reducing disruption in daily activities^{1,2}
- Sebetralstat, an oral plasma kallikrein inhibitor, has been approved for the treatment of acute HAE attacks in patients ≥ 12 years old in the US, UK, and the EU³⁻⁵
- This post hoc analysis examined the time to end of HAE attack progression following sebetralstat treatment in KONFIDENT-S and KONFIDENT
- Time to end of progression was defined as the time at which the worst attack severity was recorded within 4 hours of onset using the PGI-S scale

1. Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9(1):132-150. 2. Maurer M, et al. *Allergy*. 2022;77(7):1061-1990. 3. EKTERLY (sebetralstat). Prescribing information. KalVista Pharmaceuticals, Inc; 2025. 4. EKTERLY (sebetralstat). Summary of product characteristics. UK prescribing information. KalVista Pharmaceuticals, Inc; 2025. 5. EKTERLY (sebetralstat). Summary of Product Characteristics. EU prescribing information. KalVista Pharmaceuticals, Inc; 2025. HAE, hereditary angioedema. PGI-S, Patient Global Impression of Severity.



HAE Attack Characteristics at Time of Treatment

	KONFIDENT-S^a Sebetralstat 600 mg n=1591	KONFIDENT^b Sebetralstat 300 mg n=84	KONFIDENT^b Sebetralstat 600 mg n=88
Baseline PGI-S rating, n (%)			
Mild ^{c,d}	594 (37.3)	36 (42.9)	40 (45.5)
Moderate	668 (42.0)	33 (39.3)	30 (34.1)
Severe	262 (16.5)	12 (14.3)	16 (18.2)
Very severe	58 (3.6)	2 (2.4)	2 (2.3)
Time to treatment, median (IQR), min	14.5 (1.0-76.0)	36.0 (7.0-131.0)	38.5 (4.5-141.0)

Data from 134 participants treating 1591 attacks in KONFIDENT-S and 110 participants treating 172 attacks in KONFIDENT were analyzed

^aKONFIDENT-S: NCT05505916, EudraCT: 2021-001176-42; data cutoff: September 14, 2024. ^bKONFIDENT: NCT05259917; EudraCT: 2021-001226-21; data cutoff: January 31, 2024 ^cPGI-S rating of "None" included in "Mild": KONFIDENT-S sebetralstat 600 mg, 23 (1.4%). ^dPGI-S missing: KONFIDENT sebetralstat 300 mg, 1 (1.2%); KONFIDENT-S sebetralstat 600 mg, 9 (0.6%). IQR, interquartile range; n, number of attacks.

Time to End of Progression




The time to end of HAE attack progression closely followed the expected time to near-complete inhibition of plasma kallikrein (15 minutes) based on prior pharmacodynamic studies¹

Time to end of progression was defined as the time at which the worst HAE attack severity was recorded using the PGI-S scale within 4 hours. h, hours.

1. Aygören-Pürsün E, et al. *Lancet*. 2023;401(10375):458-469.

Time Course of Sebetralstat-treated Attacks in KONFIDENT-S



Oral sebetralstat allowed for rapid treatment and halted
HAE attack progression early

^aBased on data cutoff date of January 31, 2024. ^bBased on data cutoff date of September 14, 2024. ^cDefined as a PGI-C rating of at least “A Little Better” for at least 2 consecutive time points within 12 hours. ^dDefined as time to substantial reduction of symptom burden (PGI-S of “Mild” for 2 consecutive time points) within 24 hours. Graph generated based on median time to endpoints as observed in the KONFIDENT-S open-label extension study. Area under curve represents the HAE attack burden. Dashed line is representative of attack onset. PGI-C, Patient Global Impression of Change.